Sökning: onr:"swepub:oai:lup.lub.lu.se:5364c862-893f-44fd-a602-8c8559379f96" >
Hepatic and extrahepatic insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors
-
- Morettini, Micaela (författare)
- Marche Polytechnic University
-
- Piersanti, Agnese (författare)
- Marche Polytechnic University
-
- Burattini, Laura (författare)
- Marche Polytechnic University
-
visa fler...
-
- Pacini, Giovanni (författare)
- No affiliation available (private)
-
- Göbl, Christian (författare)
- Medical University of Vienna
-
- Ahrén, Bo (författare)
- Lund University,Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diabetes,Forskargrupper vid Lunds universitet,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups
-
- Tura, Andrea (författare)
- CNR Istituto per le Tecnologie Applicate ai Beni Culturali (CNR-ITABC)
-
visa färre...
-
(creator_code:org_t)
- 2021-08-06
- Engelska.
-
Ingår i: Biomedicines. - : MDPI AG. - 2227-9059. ; 9:8
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://www.mdpi.com...
-
https://lup.lub.lu.s...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- The aim of this study was to investigate whether incretins, at physiological levels, affect hepatic and/or extrahepatic insulin clearance. Hepatic and extrahepatic insulin clearance was studied in 31 double incretin receptor knockout (DIRKO) and 45 wild-type (WT) mice, which underwent an Intravenous Glucose Tolerance Test (IVGTT). A novel methodology based on mathematical modeling was designed to provide two sets of values (FEL-P1, CLP-P1; FEL-P2, CLP-P2 ) accounting for hepatic and extrahepatic clearance in the IVGTT first and second phases, respectively, plus the respective total clearances, CLT-P1 and CLT-P2 . A statistically significant difference between DIRKO and WT was found in CLT-P1 (0.61 [0.48–0.82] vs. 0.51 [0.46–0.65] (median [interquartile range]); p = 0.02), which was reflected in the peripheral component, CLP-P1 (0.18 [0.13–0.27] vs. 0.15 [0.11–0.22]; p = 0.04), but not in the hepatic component, FEL-P1 (29.7 [26.7–34.9] vs. 28.9 [25.7–32.0]; p = 0.18). No difference was detected between DIRKO and WT in CLT-P2 (1.38 [1.13–1.75] vs. 1.69 [1.48–1.87]; p = 0.10), neither in CLP-P2 (0.72 [0.64–0.81] vs. 0.79 [0.69–0.87]; p = 0.27) nor in FEL-P2 (37.8 [35.1–43.1] vs. 39.8 [35.8–44.2]; p = 0.46). In conclusion, our findings suggest that the higher insulin clearance observed in DIRKO compared with WT during the IVGTT first phase may be due to its extrahepatic component.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Animal model
- DIRKO
- Incretin hormones
- Insulin clearance
- IVGTT
- Mathematical model
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)